MicafunginThird Party Manufacturing in India

Micafungin works by inhibiting the synthesis of 1,3-beta-D-glucan, an essential component of fungal cell walls.

By disrupting this critical structural polymer, which is absent in mammalian cells, the drug compromises the integrity of the fungal cell wall, leading to osmotic instability and cell lysis. This biological effect helps the body clear severe, deeply invasive fungal infections.

Unlike azole antifungals, Micafungin is fungicidal against Candida species and highly active against azole-resistant strains. It is highly effective and well-tolerated for immunocompromised patients requiring systemic antifungal therapy.

Therapeutic Uses

Micafungin is prescribed for the treatment of:

• Invasive Candidiasis: Serves as a first-line treatment for severe bloodstream and systemic Candida infections.
• Esophageal Candidiasis: Effectively treats severe fungal infections of the esophagus, particularly in immunocompromised individuals.
• Prophylaxis: Used to prevent Candida infections in patients undergoing hematopoietic stem cell transplantation (HSCT).

Why Manufacturers Choose Micafungin

Micafungin is a premium, life-saving echinocandin antifungal used extensively in intensive care units and oncology wards. The high barrier to entry for manufacturing complex injectables like echinocandins ensures excellent margins and low competition.

This makes Micafungin a highly sought-after molecule for specialized third party manufacturing in India, with strong demand from critical care divisions and export markets requiring advanced sterile manufacturing capabilities.